Skip to main content
. 2023 Sep 11;34(4):2437–2444. doi: 10.1007/s00330-023-10189-y

Fig. 2.

Fig. 2

Axial slice of the lumbar spine showing T2* maps (in ms) of a patient before (A) and 6 months after (B) myelotoxic chemotherapy as well as a patient without myelotoxic chemotherapy at baseline (C) and at 6-month follow-up (D)